SFG
CORT icon

SevenBridge Financial Group’s Corcept Therapeutics CORT Stock Holding History

SevenBridge Financial Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,945
Closed -$32K – 602
2018
Q1 		$32K Sell
1,945
-55
-3% -$1.02K 0.02% 301
2017
Q4 		$36K Sell
2,000
-1,750
-47% -$31.7K 0.02% 300
2017
Q3 		$72K Buy
3,750
+650
+21% +$9.69K 0.04% 216
2017
Q2 		$37K Buy
3,100
+700
+29% +$7.61K 0.02% 300
2017
Q1 		$26K Buy
+2,400
New +$21.1K 0.02% 337

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SevenBridge Financial Group's CORT Position: Q2 2018 in Review

SevenBridge Financial Group sold out of Corcept Therapeutics (CORT) in Q2 2018, closing a stake of 1,945 shares — an estimated $32K sold.

SevenBridge Financial Group first reported a position in CORT in Q1 2017 and held it in 5 quarters. The position peaked at $72K in Q3 2017. 215 funds tracked by Wall St. Rank hold CORT as of Q2 2018.

  • SevenBridge Financial Group reported no remaining Corcept Therapeutics position as of Q2 2018 after selling out during the quarter.
  • SevenBridge Financial Group sold 1,945 Corcept Therapeutics shares in Q2 2018, an estimated $32K.
  • SevenBridge Financial Group first reported a position in Corcept Therapeutics in Q1 2017 and held it in 5 quarters.
  • SevenBridge Financial Group's Corcept Therapeutics position peaked at $72K in Q3 2017.
  • 215 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2018.

Based on SevenBridge Financial Group's 13F filing for Q2 2018, filed 14 Aug 2018.